Great Point Partners LLC

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Great Point Partners LLC
CRD #158423
SEC #801-73834
CIK #0001281446
AUM 1,777.1 M (2026-03-31)
Employees 28 (82% Investors, 14% Brokers)
Fees
Minimum
Phone203-971-3300
Address165 Mason Street
Greenwich, CT 06830
Source [IAPD] [EDGAR] [Website] [LinkedIn]
Total AUM ($B)
3.02.41.81.20.60.02010201520212027
Fees and Compensation — Form ADV Part 2A (3/31/2026) [Brochure]
ITEM 5 – FEES AND COMPENSATION
The Hedge Funds
Great Point generally receives an annual management fee of 2% of the net assets of each Hedge Fund,
generally payable in monthly installments in advance based on the Hedge Fund’s net assets on the first
day of each month. The fee is deducted from the Hedge Funds’ assets.

Great Point generally is entitled to a 20% performance allocation based on capital appreciation of the
BMVF assets, including unrealized appreciation, after deduction of expenses and subject to exceeding
the previous high-water mark. Great Point generally is entitled to a 20% performance fee based on
capital appreciation of the BMOVF assets, including unrealized appreciation, after deduction of
expenses and subject to exceeding the previous high-water mark.

In addition to the management and performance allocations/fees, the Hedge Funds incur fees and
expenses such as investment-related and other trading-related expenses (including, without limitation,
all brokerage (including prime brokerage) commissions and fees, investment banking fees and
expenses, expenses relating to short sales, clearing and settlement charges, custodial fees, bank service
fees, interest on margin accounts and other indebtedness, borrowing charges, consulting and other
professional fees relating to due diligence of particular investments or contemplated investments (in
each case whether or not the applicable investment is consummated) and reasonable travel and related
expenses incurred in connection with due diligence and other work performed on behalf of the Hedge
Fund (including premium class air travel and expenses for reasonable lodging, meals and related
items), all research-related expenses (including, without limitation, news and quotation equipment and
services, and expenses related to obtaining, processing and analyzing “big data” or “alternative data”),
data feeds, reports, subscriptions, licenses, investment-and trading-related computer hardware,
information systems, and software, including trade order management software (i.e., software used to
route trade orders), and fees and expenses of attending professional and industry conferences or
obtaining third-party research, data, analytics, modeling, structuring, pricing and execution services
that are related to the Hedge Fund’s investment activities (including any “expert network”),
professional fees (including, without limitation, expenses of attorneys, consultants, statisticians and
experts); administration expenses (including the fees and expenses of any administrator); annual
meeting expense; accounting expenses (including portfolio accounting software); organizational and
reorganizational expenses; operating expenses; including the following: fees and expenses relating to
information technology hardware, software or other technology (including costs of software licensing,
implementation, data management and recovery services and custom development) used to research
investments, evaluate and manage risk, facilitate valuations, facilitate accounting functions, facilitate
compliance with the rules of any self-regulatory organization or applicable law (including reporting
obligations), facilitate and manage the order execution of securities or otherwise manage the Fund or
any trading vehicle, such as Bloomberg terminals, portfolio management systems, risk management
systems and order management systems; fees and expenses of third-party risk management products,
models and services; third-party administrative fees and expenses; audit expenses; legal expenses; fees
and expenses associated with the preparation or distribution of the Fund’s financial statements, tax

returns, tax estimates and Schedules K-1 and, if applicable, K-3, any reporting to the limited partners
or any other administrative, regulatory or other Hedge Fund -related reporting or filing (including
Section 13 filings), any investor administrative tools such as investor portals and third-party reporting
software; communications expenses, and any Fund-related filings or reports required by the
Alternative Investment Fund Managers Directive of the European Union or any similar law, rule or
regulation and expenses related to compliance with such; costs of printing and mailing reports and
notices; corporate licensing; all fees, expenses, costs and liabilities incurred in connection with
litigation, arbitration, mediation, claim, proceeding or other extraordinary events involving the Hedge
Fund; governmental fees and regulatory expenses (including filing fees);charges, and all expenses
incurred by Great Point in its capacity as the Hedge Fund’s tax matters partner, or a similar role under
applicable state or local tax law; expenses incurred in connection with the offering and sale of the
interests in the Hedge Fund and other similar expenses related to the Hedge Fund; premiums for
liability insurance (including directors and officers and errors and omissions insurance) covering Great
Point and its affiliates and their respective members, directors, officers, employees and agents and
other indemnity expenses (including attorney’s fees incurred in connection therewith); the
management fee and the incentive allocation; costs of preparing and distributing reports and notices;
taxes; expenses incurred in connection with negotiating and complying with provisions of any side
letter agreement; and extraordinary expenses and other similar expenses related to the Hedge Fund as
Great Point determines in its sole discretion , including the following: indemnification expenses; fees
and expenses incurred in connection with any tax audit by any taxing authority, including any related
administrative settlement and judicial review; and fees and expenses incurred in connection with the
reorganization, dissolution, winding up or termination of the Hedge Fund or any trading vehicle.
Specific information regarding the management fees, performance allocations/fees and expenses for
...
Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2026) [Brochure]
ITEM 7 – TYPES OF CLIENTS
Great Point provides advisory services to private funds that are considered hedge funds or private
equity funds. The investors participating in the Funds generally include individuals, banks or thrift
institutions, other investment entities, university endowments, sovereign wealth funds, family offices,
pension or profit-sharing plans, trusts, estates, or charitable organizations or other corporations or
business entities, and include, directly or indirectly, principals or other employees of Great Point and
its affiliates and members of their families, as well as service providers or other relationships retained
by Great Point including members of the Medical Advisory Board and the CEO Advisory Board. Great
Point does not provide investment advice directly to investors in the Funds on an individual basis.
Great Point also from time to time provides advisory services to Managed Accounts which in such a
case will be institutional investors. The Hedge Funds and the Private Equity Funds generally require
a minimum initial subscription from investors and require them to meet suitability requirements. For
a Managed Account, Great Point generally requires a significant minimum investment. Great Point
may waive minimum account sizes in its sole discretion.
Sector Form 13F Holdings Value ($M)
Apogee Therapeutics Inc 31.5
Vor Biopharma Inc 31.2
JATT Acquisition Corp 25.1
Amylyx Pharmaceuticals Inc 24.3
Nantkwest Inc 23.0
Nektar Therapeutics 22.8
Sol-Gel Technologies Ltd 21.7
Alumis Inc 18.9
Bright Minds Biosciences Inc 16.1
Annexon Inc 13.8
View All
Holdings by Sector ($M)
1300104078052026002011201620212027
Type Form D Funds Date Sold AUM
PE GPP IV - Eutecma LLC 2026-03-31 1.0 M
PE GPP IV - Lyocontract LLC 2025-03-28 77.7 M
PE GPP IV - LUDI LLC 2024-10-14 4.6 M
PE GPP - CF I LP [2023-03-31] 36.4 M 25.6 M
Offered $36,415,770 · Filed 2022-12-12 (D) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Revenue Decline to Disclose
PE GPP III - Ephicacy LLC 2023-03-31 21.9 M
PE GPP III - Ixcells LLC 2023-03-31 1.8 M
PE Great Point Partners IV LP [2022-05-05] 432.0 M 658.5 M
Offered $500,000,000 · Filed 2022-04-15 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining $68,030,000 · Duration One year or less · Commission $680,000 · Revenue Decline to Disclose
PE GPP III - PCM LLC 2022-03-31 40.2 M
PE GPP II-A Salmon AIV LP 2021-02-25 20.6 M
PE GPP III - MLM LLC 2021-02-25 5.4 M
View All
AUM Breakdown Accounts AUM ($B)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 17 1.8
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 17 1.8
By Discretionary
Discretionary 17 1.8
Non-Discretionary 0 0.0
Total 17 1.8
By Non-United States Persons
Non-United States Persons 0.2
United States Persons 1.6
Total 17 1.8
Form D Directors Role # Filings # Firms 2011 - 2026
Riyaz Nooruddin Director 61 22
Alan Kelly Director 39 17
Charl Grobler Director 7 5
Jeffrey Jay Director, Executive Officer 12 2
David Kroin Executive Officer 7 2
Great Point Partners LLC Executive Officer, Promoter 3 2
Great Point GP LLC Executive Officer 2 2
Great Point Partners CF I GP LLC Promoter 1 1
EDGAR Form CIK 2011 - 2026
13F-HR [0001281446]
13F-NT [0001281446]
3 [0001281446]
4 [0001281446]
SC 13D [0001281446]
SC 13G [0001281446]
Form 13D/13G Filer Form 13D/13G Subject Filed
Great Point Partners LLC Amanat Acquisition Corp [2026-05-27]
Great Point Partners LLC Promis Neurosciences Inc [2026-05-15]
Great Point Partners LLC JATT II Acquisition Corp [2026-04-24]
Great Point Partners LLC Scynexis Inc [2026-04-07]
Great Point Partners LLC Sol-Gel Technologies Ltd [2026-03-31]
Great Point Partners LLC Vor Biopharma Inc [2025-12-17]
Great Point Partners LLC Inventiva Sa [2025-06-20]
Great Point Partners LLC ZURA Bio Ltd [2025-05-14]
Great Point Partners LLC Elevation Oncology Inc [2024-08-15]
Great Point Partners LLC Promis Neurosciences Inc [2024-08-05]
View All
Firm Profile (Form ADV)
Discretionary AUM$0.9B
ServesInstitutional
Fund TypesHedge Fund, Private Equity
Form 3/4/5 Subject 2011 - 2026
Kroin David
Great Point Partners LLC
Foamix Pharmaceuticals Ltd
Jay Jeffrey R
Adamas Pharmaceuticals Inc
Apyx Medical Corp
Sheffield Ian
Great Point Partners I LP
Great Point Partners I GP LLC
Connecture Inc
GPP - Connecture LLC
WaferGen Bio-systems Inc
Pesce Joseph F
Davidson Scott Richard
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Adamas Pharmaceuticals Inc ADMS
Common Stock
2017-06-21 Sell 10,000 $17.44 174,400
Adamas Pharmaceuticals Inc ADMS
Common Stock
2017-06-20 Sell 20,000 $17.35 347,000
Adamas Pharmaceuticals Inc ADMS
Common Stock
2017-06-19 Sell 350,000 $17.05 5,967,500
Connecture Inc CNXR
Common Stock
2015-06-30 Gift 10,000 $0.00
Connecture Inc CNXR
Common Stock
2015-06-10 Other 1,375,733 $0.00
Connecture Inc CNXR
Common Stock
2015-06-10 Other 39,703 $0.00
Connecture Inc CNXR
Common Stock
2015-06-10 Other 47,235 $0.00
Connecture Inc CNXR
Common Stock
2015-06-10 Other 36,493 $0.00
Connecture Inc CNXR
Common Stock
2015-06-10 Other 28,696 $0.00
Apyx Medical Corp BVX
Series B Convertible Preferred Stock · derivative
2015-03-17 Grant 3,588,139
Apyx Medical Corp BVX
Common Stock
2015-03-17 Grant 480,000 $2.50 1,200,000
Apyx Medical Corp BVX
Common Stock Warrants (right to buy) · derivative
2015-03-17 Disposed to issuer 5,250,000
Apyx Medical Corp BVX
Series A Convertible Preferred Stock · derivative
2015-03-17 Disposed to issuer 3,500,000
Connecture Inc CNXR
Series B Preferred Stock · derivative
2014-12-17 Conversion 17,696,553 $0.00
Connecture Inc CNXR
Common Stock
2014-12-17 Sell 395,886 $8.00 3,167,088
Connecture Inc CNXR
Common Stock
2014-12-17 Conversion 5,898,851
Apyx Medical Corp BVX
Stock Option (Option to Buy) · derivative
2014-07-17 Grant 12,000 $0.00
WaferGen Bio-systems Inc WGBS
Common Stock
2013-11-15 Conversion 899,893
WaferGen Bio-systems Inc WGBS
Common Stock
2013-11-15 Conversion 899,893
WaferGen Bio-systems Inc WGBS
Series 1 Convertible Preferred Stock · derivative
2013-11-15 Conversion 357.76
showing 20 of 39 most recent transactions
Comparable Firms State AUM
D2 Asset Management LP
TX 1,825.9 M
ParaFi Capital LP
NY 1,817.8 M
Tensile Capital Management LP
CA 1,796.0 M
Morgan Creek Capital Management LLC
NC 1,790.2 M
QVT Financial LP
NY 1,786.7 M
Alta Park Capital LP
CA 1,779.6 M
OFS Capital Management LLC
IL 1,760.0 M
RCF Management LLC
CO 1,757.0 M
Parkman Healthcare Partners LLC
CT 1,744.0 M
Long Path Partners LP
CT 1,732.8 M
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com